Healthcare News South Africa

Ferring aims for market share growth with X/procure®

Specialty biopharmaceutical group, Ferring South Africa, recently partnered with Primedia-Unlimited subsidiary X/procure® for an initial one year period to promote Pentasa, its latest treatment option for Inflammatory Bowel Disease. Via X/procure's® innovative electronic procurement system, Ferring has gained direct access to a national network of pharmacists.

Says Hardus van Vuuren, Business Unit Manager for Ferring South Africa “We consider ourselves specialists in the management of Inflammatory Bowel Disease, and our partnership with X/procure® will allow us to fulfil our global vision of becoming Partners of Choice. X/Procure's® system provides us with the ideal opportunity to create added awareness of our products and to be a dominant presence in an otherwise already cluttered pharmaceutical environment.”

“It was decided at a strategy session held with the client that the Ferring campaign would be themed the Seven Wonders of the World and the best way to optimise the campaign's effectiveness and interactivity with pharmacists would be to use a combination of advertising media,” says Sales and Marketing Director of X/procure® JD Henderson.

“The amalgamation of Intervention ads, screen savers and banners appearing directly on the pharmacist's electronic ordering screens, create high frequency communication and greater awareness of Pentasa.”

Ferring South Africa is an international Swiss based and research driven biopharmaceutical group. The organisation identifies, develops and markets ground-breaking products in the areas of endocrinology, gastroenterology, gynaecology, fertility and urology.

X/procure®
Deon Lewis
T: +27 11 562 6500



Editorial contact

Chirene Campbell
T: +27 11 234 6520

Let's do Biz